Skip to main content

Market Overview

Biogen: Q4 Earnings Insights



Shares of Biogen (NASDAQ:BIIB) decreased 0.7% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share decreased 45.08% over the past year to $4.58, which missed the estimate of $4.87.

Revenue of $2,852,600,000 decreased by 22.29% from the same period last year, which beat the estimate of $2,800,000,000.


Biogen said it sees FY21 adjusted EPS of $17-$18.50 and sales of $10.45 billion-$10.75 billion.

How To Listen To The Conference Call

Date: Feb 03, 2021

Time: 08:00 AM

ET Webcast URL:

Price Action

Company's 52-week high was at $374.99

Company's 52-week low was at $223.25

Price action over last quarter: Up 3.36%

Company Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.


Related Articles (BIIB)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at